A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. - Wikidata - wikimedia - TriplyDB

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

http://www.wikidata.org/entity/Q36070261

about

Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity Advances in immunotherapy for treatment of lung cancer Development of Novel Immunotherapies for Multiple Myeloma Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Improving natural killer cell cancer immunotherapy Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Immune checkpoint blockade for hematologic malignancies: a review NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27 Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.The head and neck cancer immune landscape and its immunotherapeutic implications.Role of Natural Killer Cells in HIV-Associated Malignancies.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.Immunologic approaches for the treatment of multiple myeloma.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?Control of NK Cell Activation by Immune Checkpoint Molecules.Trial watch: Immune checkpoint blockers for cancer therapy.Innate immune cells for immunotherapy of autoimmune and cancer disorders.KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Emerging immune targets for the treatment of multiple myeloma.A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.Tumor immunotherapy: New aspects of natural killer cells.Next generation immune-checkpoints for cancer therapy.Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells Unchaining NK cell–mediated anticancer immunosurveillance

P2860

Q26747397-1205A1E9-0A34-4A2B-891F-35ED176736CB Q26751011-C0161F5A-2637-438C-B468-65E49B1C85A6 Q26752518-69B845CD-04A0-44D7-A533-074513F755E4 Q26773135-EE871C0F-CCA0-48E3-B490-2A0644CEC3A3 Q26778790-988C8500-E811-44A3-A8BB-09727A27C8BF Q28066890-517627D7-1DAC-44CE-A923-39A7DE342953 Q28079180-9F42F5E3-E1A4-4870-B6CC-9D865F5BB475 Q28087719-D19BBB43-8CAD-4626-8758-F9451C0BD932 Q30275870-6BC4DA19-ED20-4D55-A9A0-FF6C429C3265 Q33645590-34A174A9-515A-4422-9138-F423AF5EAC81 Q33798745-531E4FE9-C194-4B63-96AE-72C8116E2671 Q36245682-3775D19E-0DC0-445D-930B-33705B78DDF6 Q37351606-69284DFC-F1FF-432C-9BE6-D61BDE31612A Q37712593-20F5C655-6D5D-4B91-8BD6-A7B23486BE41 Q38599353-D0130515-204B-4346-BF0A-EE2A198EA3BC Q38692244-1A129037-7390-47A1-B79A-63957129BA89 Q38708402-3313EC45-901F-4728-AB35-4449E41945EF Q38737970-06A5F610-9708-40AF-8D1E-531CB8BA89F7 Q38928938-DBE65678-5B1B-4F69-B3C2-F10F4943E430 Q38958563-AB3D6321-BE7D-4626-A11E-4C878DD06F02 Q39136762-0B4CBC8E-183F-4778-85DC-2E93CFCF1487 Q39138108-483ED759-02B4-4B9C-856E-4C5A4150007B Q39174731-CB9AE4BC-0D22-419D-A7CF-B5A1947E6831 Q41714691-55759FA2-B785-4455-AA08-A083A5D621E3 Q42042886-598DAF73-01FD-42BA-90C2-7A1D5654CFA6 Q42660142-31106CED-1488-4EE1-ABC8-E28F2D73EE6E Q42684464-C259CB23-309E-44EC-9468-8ABF4527F177 Q47128718-6E0B4563-754C-431B-A8C9-8A727455E677 Q47393365-8DED6CF0-32CD-4373-9C03-EDDDC92B8839 Q48316500-71906AFC-BD71-4518-8A38-47D37B13A6E8 Q48361273-0DEF0237-0771-4FC0-AE54-C7B5495CA759 Q48590636-F5BDDA90-24ED-4B82-A9BC-1C83F2EB2CF6 Q49830211-F9C0849B-6390-48F4-AFC6-4EF877D514AA Q50025144-4B3E0509-781B-41FD-A580-62BAE285D57C Q54943618-14C17C39-1A6A-4AF3-88B9-BA50A17A89C1 Q55042057-4BFB4FA7-C45D-47F9-BDEC-02CB0273CB33 Q55107050-B2321666-C395-469E-BF25-991AB3468234 Q55383705-83E365C9-756B-4DF2-9448-23860471B294 Q56889003-CD59DD4B-DC65-4F61-9BF7-4FFA6CF0601B Q57082741-9BE03FCF-6B25-4C4A-A3EA-CAFB7306C2CE

P2860

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

http://www.wikidata.org/entity/Q36070261

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.

@ast

A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.

@en

type

label

A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.

@ast

A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.

@en

prefLabel

A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.

@ast

A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.

@en

P1433

Q36070261-90DFF41E-543B-4358-8716-50F6C1BF0839

P1476

Q36070261-4D74C28E-5DF5-4040-9732-08635E6BE2B9

P2093

Q36070261-0668F9D6-B706-4B1E-BAB4-E11FF9068507

Q36070261-23FEB4F2-058D-4356-97D2-0726EF7BEBE8

Q36070261-4B375037-DC9B-43E9-A614-95138D404C44

Q36070261-4C193D6D-9AF7-4113-A741-8BEA9E2A83DE

Q36070261-6343A770-10D9-4B09-86FE-239D4BEA9EA6

Q36070261-7100D049-3BF6-41CF-AFCF-B8DC3C90D6F3

Q36070261-B9BACBE5-D75B-4BE1-BBCD-C169522F78CC

Q36070261-C15D7539-6C1D-4F6B-84BD-8FE3318FB8D2

Q36070261-C4D36793-DDAF-4ECA-A7D2-8AAD1F569130

P2860

Q36070261-01C311A1-0369-4751-AA28-227FB99140F7

Q36070261-0F24F331-36C2-4E8F-B59C-456BA18876E0

Q36070261-26433204-7DC1-4638-B9A4-EA785A8249E2

Q36070261-2861671C-329D-439C-AFD6-131E3A5005AE

Q36070261-3CA26AD3-0CEC-40B4-B5B1-9CA0A44FA2A5

Q36070261-4A5B8D26-AA6C-46C7-AD67-22BB3A1E3250

Q36070261-4ACE7657-1938-4BA0-AF39-A005B4F6D0D4

Q36070261-686AD233-6244-4F15-89E3-831597C74A35

Q36070261-6C8E6350-BADD-47AD-BFC1-224DDA31A590

Q36070261-7013A7A4-361E-411A-ACE7-F2ED0B714AE0

P304

Q36070261-96E5D89E-330D-479B-91E6-46A5B311CA87

P31

Q36070261-235290D9-5B39-4235-9565-F1A5A371E0A1

P356

Q36070261-1201ABBC-0E28-467D-892C-1DA0E5E2A313

P407

Q36070261-E0F8F501-D09B-4A95-8493-6FBF83310F34

P433

Q36070261-29905CD6-755E-42FF-B50F-AE59B2E15807

P478

Q36070261-ACD6C552-CE15-434C-957B-18A3AD2278E2

P50

Q36070261-575A40D6-23DF-48E8-9045-248653715E26

P577

Q36070261-158BD5B5-763B-44A3-A404-248DA16F109B

P698

Q36070261-531E1452-2896-44C5-B758-6399A8A043A3

P921

Q36070261-79D2D124-B1C2-40FA-9D69-111BE08E8823

Q36070261-85EB0C07-D5F9-44CA-8686-2F1D31BFABDD

P932

Q36070261-13B9DD47-3D90-48C8-9F4F-D5404168A21E

P356

1078-0432.CCR-15-0304

P1433

Clinical Cancer Research

P1476

A Phase I Trial of the Anti-KI ...... ed/Refractory Multiple Myeloma

@en

P2093

Craig C Hofmeister

http://www.w3.org/2001/XMLSchema#string

Don M Benson

http://www.w3.org/2001/XMLSchema#string

Gary Spitzer

http://www.w3.org/2001/XMLSchema#string

Michael A Caligiuri

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Pascale Andre

http://www.w3.org/2001/XMLSchema#string

Robert Zerbib

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

Yvonne A Efebera

http://www.w3.org/2001/XMLSchema#string

P2860

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Improved survival in multiple myeloma and the impact of novel therapies.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

P304

4055-4061

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-0304

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25999435

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4573800

http://www.w3.org/2001/XMLSchema#string